Abstract
Early diagnosis of the different severities of septic inflammation is important for early implementation of specific therapies. Sepsis and severe sepsis are accompanied by clinical and laboratory signs of systemic inflammation. However, patients suffering from non-infectious inflammation may present with similar signs and symptoms, making it difficult to diagnose infection based on clinical findings alone. Bacteriological evidence of sepsis, although definitive and specific, may not be obtainable, is time consuming, and may not occur concurrently with clinical signs of sepsis. It is therefore important to identify markers, which, by enabling an early diagnosis of sepsis and organ dysfunction, would allow early specific therapeutic interventions. Whereas C-reactive protein (CRP) is a more-sensitive parameter for the diagnosis of non-systemic infections, procalcitonin (PCT) seems to be a useful parameter to improve the diagnosis and monitoring of therapy in patients with severe sepsis and septic shock.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Reimer LG, Wilson ML, Weinstein MP (1997) Update on detection of bacteremia and fungemia. Clin Microbiol Rev 10: 444 465
Rangel-Frausto MS, Pittet D, Costigan M, et al (1995) The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273: 117–123
Reyes WJ, Brimioulle S, Vincent J-L (1999) Septic shock without documented infection: an uncommon entity with a high mortality. Intensive Care Med 25: 1267–1270
American College of Chest Physicians-Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 328: 864–875
Abraham E, Matthay MA, Dinarello CA, et al (2000) Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit Care Med 28: 232–235
Wakefield CH, Barclay GR, Fearon KC, et al (1998) Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra-abdominal sepsis. Scottish Sepsis Intervention Group. Br J Surg 85: 818–825
Paulus WJ (1999) How are cytokines activated in heart failure? Eur J Heart Fail 309–312
Hamano K, Gohra H, Noda H, et al (1998) Increased serum interleukin-8: correlation with poor prognosis in patients with postoperative multiple organ failure. World J Surg 22: 1077–1081
Reinhart K, Wiegand-Lohnert C, Grimminger F, et al (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment. MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24: 733–742
Panacek E, Albertson T, Johnson D, et al (2000) Septest, a rapid, immunostrip test for serum IL-6 concentrations, prospectively defined a population of patients with sepsis at greater risk for mortality in the MONARCS (monoclonal anti-TNF: a randomized controlled sepsis) trial. Poster presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada
Hack CE, De-Groot ER, Felt-Bersma RJ, et al (1989) Increased plasma levels of interleukin-6 in sepsis. Blood 74: 1704–1710
Hasper D, Hummel M, Kleber FX, et al (1998) Systemic inflammation in heart failure. Eur Heart J 19: 761–765
Engel A, Mack E, Kern P, Kern WV (1998) An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection 26: 213–221
Berner R, Niemeyer CM, Leititis JU, et al (1998) Plasma level and gene expression of granulocyte colony-stimulating factor, tumor necrosis factor-alpha, interleukin (IL)-lbeta, IL-6, IL-8, and soluble intercellular adhesion molecule-1 in neonatal early onset sepsis. Pediatr Res 44: 469–477
Rau B, Steinbach G, Gansauge F, et al (1997) The role of procalcitonin and interleukin-8 in the prediction of infected necrosis in acute pancreatitis. Gut 41: 832–840
Shenkin A, Fraser WD, Series J, et al. (1989) The serum interleukin-6 response to elective surgery. Lymphokine Res 42: 446–454
Nast-Kolb D, Waydhas C, Gippner-Steppert C, et al (1997) Indicators of the posttraumatic inflammatory response correlate with organ failure in patients with multiple injuries. J Trauma 42: 446–454
Kutukculer N, Caglayan S, Aydogdu F. (1998) Study of pro-inflammatory (TNF-alpha, IL 1 alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin Rheumatol 17: 288–292
Robak T, Glaalska A, Stepien H, Robak E. (1998) Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm 7: 347–353
Gendrel D, Raymond J, Assicot M, et al (1997) Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis 24: 1240–1242
Malaguarnera M, Di Fazio I, Romeo MA, et al (1997) Elevation of interleukin-6 in patients with chronic hepatitis due to hepatitis C virus. J Gastroenterol 32: 211–215
Kita Y, Iwaki Y, Noguchi K, et al (1996) Daily serum interleukin-6 monitoring in multiple organ transplantation with or without liver allografts. Transplant Proc 28: 1229–1234
Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448–454
Dev D, Wallace E, Sankaran R, et al (1998) Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 92: 664–667
Shaw AC (1991) Serum C-reactive protein and neopterin concentrations in patients with viral or bacterial infections. J Clin Pathol 44: 596–599
Povoa P, Almeida E, Moreira P, et al (1998) C-reactive protein as an indicator of sepsis. Intensive Care Med 24: 1052–1056
Erikson S, Granstrom L, Olander B, Wretlind B, (1995) Sensitivity of interleukin-6 and C-reactive protein concentrations in the diagnosis of acute appendicitis. Eur J Surg; 161: 41–45
Brunkhorst FM, Heinz U, Forcki ZF (1998) Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med 24: 888–889
Monneret G, Labaune JM, Isaac C, et al (1997) Procalcitonin and C-reactive protein levels in neonatal infections. Acta Paediatr 86: 209–212
Meisner M, Tschaikowsky K, Palmaers T, Schmidt J (1999) Comparison of procalcitonin (PCT) and C-reactive protein ( CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care 3: 45–55
Ugarte H, Silva E, Mercan D, et al (1999) Procalcitonin used as a marker in the intensive care unit. Crit Care Med 27: 498–504
Meisner M, Tschaikowsky K, Palmaers T, Schmidt J (1999) Comparison of procalcitonin (PCT) and C-reactive protein ( CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care 3: 45–55
Eberhard OK, Haubitz M, Brunkhorst FM, et al (1997) Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmatic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 40: 1250–1256
Schwener V, Sis J, Breitbart A, Andrassy K (1998) CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection 26: 274–276
Lindahl B, Toss H, Siegbahn A, et al. for the FRISC study group (2000) Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 343: 1139–1147
Meisner M, Tschaikowsky K, Hutzler A, et al (1998) Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med 24: 680–684
Meisner M, Tschaikowsky K, Beier W, Schüttler J (1996) Procalcitonin ( PCT) — ein neuer Parameter zur Diagnostik und Verlaufskontrolle von bakteriellen Infektionen und Sepsis. Anästh Intensivmedizin 10: 529–539
Gramm HJ, Dollinger P, Beier W (1995) Procalcitonin: ein neuer Marker der inflammatorischen Wirtsantwort. Longitudinalstudien bei Patienten mit Sepsis und Peritonitis. Chir Gastroenterol 11 [Suppl 2]: 51–54
Assicot M, Gendrel D, Carsin H, et al (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341: 515–518
Dandona P, Nix D, Wilson MF, et al (1994) Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79: 1605–1608
Oberhoffer M, Stonans I, Russwurm S, et al (1999) Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis related cytokines in vitro. J Lab Clin Med 134: 49–55
Müller B, White JC, Nylen ES, et al. (2001) Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 86: 396–404
Nylen ES, Whang KT, Snider Jr RH, et al (1998) Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 26: 1001–1006
Beaune G, Bienvenue C, Pondarre G, et al (1998) Serum procalcitonin rise is only slight in two cases of disseminated aspergillosis. Infection 26: 168–169
Meisner M, Tschaikowsky K, Schnabel S, et al (1997) Procalcitonin: influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations. Eur J Clin Chem Clin Biochem 35: 597–601
Meisner M. (2000) Procalcitonin. A new, innovative infection parameter, 3rd edn, Thieme Verlag Stuttgart
Werra I de, Jaccard C, Corradin SB, et al (1997) Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 25: 607–603
Müller B, Becker KL, Schächinger H, et al (2000) Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 28: 977–983
Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R (2000) Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 26 [Suppl]:S 148 - S152
Al-Nawas B, Krammer I, Shah PM (1996) Procalcitonin in diagnosis of severe infections. Eur J Med Res 1: 331–333
Gramm HJ, Hannemann L (1996) Activity markers for the inflammatory host response and early criteria of sepsis. Clin Intensive Care 7 [Suppl 11:1–320–321
Reith HB, Mittelkötter U, Debus ES, et al (1998) Procalcitonin in early detection of postoperative complications. Dig Surg 5: 260–265
Chiesa C, Panero A, Rossi N, et al (1998) Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis 26: 664–672
Brunkhorst FM, Clark AL, Forycki ZF, Anker SD. (1999) Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. Int J Cardiol 72: 3–10
Brunkhorst FM, Niebauer J, Anker SD (1999) Endotoxin and immunactivation in chronic heart failure (letter). Lancet 354: 599–600
Loebe M, Lodziewski S, Brunkhorst FM, et al. (2000) Procalcitonin (PCT) in cardiac surgery. In: Bakut D, Krian A (eds.) Current perspectives of the extracorporeal circulation. Springer Berlin Heidelberg New York, pp 127–135
Oberhoffer M, Karzai W, Meier-Hellmann A, et al (1999) Sensitivity and specifity of various markers of inflammation for the prediction of tumor necrosis factor alpha and interleukin-6 in patients with sepsis. Crit Care Med 27: 1814–1818
Wanner GA, Keel M, Steckholzer U, et al. (2000) Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med 28: 950–957
Loebe M, Lociewski S, Brunkhorst FM, et al (2000) Procalcitonin in patients undergoing cardiopulmonary bypass in open heart surgery-first results of the Procalcitonin in Heart Surgery study (ProHearts). Intensive Care Med 26 [Supp 2]: 193–198
Brunkhorst FM, Eberhard OK, Brunkhorst R (1999) Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med 27: 2172–2176
Eberhard OK, Langefeld I, Kuse E, et al (1998) Procalcitonin in the early phase after renal transplantation: will it add to diagnostic accuracy? Clin Transplant 12: 206–211
Kuse E-R, Langefeld I, Jager K, Külpmann WR (2000) Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med 28: 555–559
Hammer S, Meisner F, Dirschedl P, et al (1998) Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation.Transpl Immunol 6: 235–241
Al-Nawas B, Shah PM (1996) Procalcitonin in patients with and without immunosuppression and sepsis. Infection 24: 434–436
Hack CE, Nuijens JH, Felt-Bersma RJ, et al (1989) Elevated plasma concentrations of the anaphylatoxins C3a and C4a are associated with a fatal ourtcome in sepsis. Am J Med 86: 20–26
Selberg O, Hecker H, Martin M, et al (2000) Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med 28: 2793–2798
Pacher R, Redl H, Fraas M, et al (1989) Relationship between neopterin and granuolcyte elastase plasma levels and the severity of multiple organ failure. Crit Care Med 17: 221–226
Janoff A (1985) Elastase in tissue injury. Annu Rev Med 36: 207–216
Gardinali M, Padalino P, Suffredini A, et al (1992) Complement activation and polymorphonuclear neutrophil leucocyte elastase in sepsis. Arch Surg 127: 1219–1224
Fuchs D (1992) The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 29: 307–341
Fuchs D, Hausen A, Reibnegger G, et al (1998) Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 9: 150–155
Döcke WD, Randow F, Syrbe U, et al (1997) Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3: 678–681
Volk HD, Reinke P, Krausch D, et al (1996) Monocyte deactivation—rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22[Supp1]4: S474 - S481
Haupt W, Riese J, Mehler C, et al (1998) Monocyte function before and after surgical trauma. Dig Surg 15: 102–104
Asadullah K, Woiciechowsky C, Döcke WD, et al (1995) Immunodepression following neurosurgical procedures. Crit Care Med 23: 1976–1983
Uhl W, Beger HG, Hoffmann G, et al (1995) A multicenter study of phospholipase A2 in patients in intensive care units. J Am Coll Surg 180: 323–331
Rinalta EM, Nevalainen TJ (1993) Group II phospholipases in sera of febrile patients with microbiologically or clinically documented infections. Clin Infect Dis 269: 278–288
Yang HC, Mosior M, Johnson CA, et al (1999) Group-specific assays that distinguish between the four major types of mammalian phospolipase A2. Ann Biochem 269: 278–288
Cohen J (2000) The detection and interpretation of endotoxaemia. Intensive Care Med; 26: S51 - S56
Romaschin AD, Harris DM, Ribeiro MB, et al (1998) A rapid assay of endotoxin in whole blood using autologous neutrophil-dependent chemiluminescence. J Immunol Methods 212: 169–185
Schumann RR, Leong SR, Flaggs GW, et al (1990) Structure and function of lipopolysaccaride binding protein. Science 249: 1429–1431
Pugin J, Heumann D, Tomasz A et al (1994) CD14 is a pattern recognition receptor. Immunity 1: 509–516
Opal SM, Scannon PJ, Vincent J-L, et al (1999) Relationship between plasma levels of lipopolysaccaride ( LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 180: 1584–1589
Erwin PJ, Lewis H, Dolan S, et al (2000) Lipopolysaccaride binding protein in acute pancreatitis. Crit Care Med 28: 104–109
Bernard GR, Vincent J-L, Laterre P-F, et al (2001) For the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety for recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699–709
Fisher CJ, Yan B (2000) Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 28 [Suppl]: S49–556
Matot I, Sprung CL (2001) Definition of sepsis. Intensive Care Med 27 [Suppl]: S3–59
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Italia, Milano
About this paper
Cite this paper
Brunkhorst, F.M., Reinhart, K. (2002). Diagnostic Approach to Sepsis — State of the Art. In: Baue, A.E., Berlot, G., Gullo, A., Vincent, JL. (eds) Sepsis and Organ Dysfunction. Springer, Milano. https://doi.org/10.1007/978-88-470-2213-3_13
Download citation
DOI: https://doi.org/10.1007/978-88-470-2213-3_13
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0178-7
Online ISBN: 978-88-470-2213-3
eBook Packages: Springer Book Archive